DeepMed Research

Manhattan Eye, Ear & Throat Hospital

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study

Not Applicable

Conditions: Retinal Vascular Disorders

Interventions: Drug: Visudyne

First Posted Date: 2013-11-01

Last Posted Date: 2013-11-01

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 30

Registration Number: NCT01974622

Locations: 🇺🇸
Vitreous Retina Macula Consultants of New York, New York, New York, United States

Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy

Not Applicable

Withdrawn

Conditions: Pattern Dystrophy of Macula

Interventions: Drug: aflibercept

First Posted Date: 2013-10-18

Last Posted Date: 2014-12-31

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Registration Number: NCT01965041

Locations: 🇺🇸
Ns/Lij Meeth, New York, New York, United States

Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

Phase 1

Completed

Conditions: Chronic Central Serous Chorioretinopathy

Interventions: Drug: Anecortave Acetate Sterile suspension 15 mg
Drug: Anecortave Acetate

First Posted Date: 2007-06-21

Last Posted Date: 2012-10-25

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 5

Registration Number: NCT00489840

Locations: 🇺🇸
Manhattan Eye, ear & Throat Institute, New York, New York, United States
🇺🇸
Vitreous-Retina-Macula Consultants of New York,PC, New York, New York, United States

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

Phase 1

Completed

Conditions: Coats' Disease
Idiopathic Retinal Telangiectasia
Retinal Angiomatous Proliferation
Polypoidal Choroidal Vasculopathy
Pseudoxanthoma Elasticum
Pathological Myopia
Multi-focal Choroiditis
Rubeosis Iridis
Von Hippel Lindau Disease
BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)

Interventions: Drug: ranibizumab injection (0.5 mg)

First Posted Date: 2007-05-08

Last Posted Date: 2012-10-25

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 18

Registration Number: NCT00470977

Locations: 🇺🇸
Lenox Hill Hospital/Manhattan Eye, Ear & Throat Institute, New York, New York, United States
🇺🇸
Lenox Hill Hospital/Manhattan Eye Ear and Throat Institute, New York, New York, United States

Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)

Phase 2

Completed

Conditions: Coat's Disease

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-24

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 4

Registration Number: NCT00211315

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

Phase 2

Completed

Conditions: Macular Degeneration

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-25

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Registration Number: NCT00211458

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole

Phase 2

Completed

Conditions: Chronic Central Serous Chorioretinopathy

Interventions: Drug: ketoconazole

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-25

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 5

Registration Number: NCT00211393

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Phase 2

Completed

Conditions: Pseudovitellium Detachment
Eye Diseases

Interventions: Drug: Anecortave Acetate Sterile Suspension (15 mg)

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-25

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 4

Registration Number: NCT00211432

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Phase 1

Completed

Conditions: Maculopathy, Age-Related

First Posted Date: 2005-09-21

Last Posted Date: 2012-10-24

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Registration Number: NCT00211419

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).

Phase 2

Completed

Conditions: Idiopathic Perifoveal Telangiectasia

First Posted Date: 2005-09-21

Last Posted Date: 2009-02-04

Lead Sponsor: Manhattan Eye, Ear & Throat Hospital

Target Recruit Count: 5

Registration Number: NCT00211328

Locations: 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy